These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35807545)

  • 21. Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses.
    Gupta A; Sahu N; Singh AP; Singh VK; Singh SC; Upadhye VJ; Mathew AT; Kumar R; Sinha RP
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6386-6406. PubMed ID: 35921031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An
    Clemente CM; Freiberger MI; Ravetti S; Beltramo DM; Garro AG
    J Biomol Struct Dyn; 2022 Aug; 40(12):5653-5664. PubMed ID: 33459192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational Screening of Inhibitory Compounds for SARS-Cov-2 3CL Protease with a Database Consisting of Approved and Investigational Chemicals.
    Miwa K; Guo Y; Hata M; Yamamoto N; Hoshino T
    Chem Pharm Bull (Tokyo); 2023; 71(5):360-367. PubMed ID: 37121686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular docking and simulation studies of natural compounds of
    Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Inhibitors from Nigella Sativa.
    Baig A; Srinivasan H
    Appl Biochem Biotechnol; 2022 Mar; 194(3):1051-1090. PubMed ID: 35102539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of Laurusides 1 and 2 with the 3C-like Protease (M
    Autiero I; Roviello GN
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982585
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
    Hassan A; Arafa RK
    J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.
    Naik SR; Bharadwaj P; Dingelstad N; Kalyaanamoorthy S; Mandal SC; Ganesan A; Chattopadhyay D; Palit P
    J Biomol Struct Dyn; 2022 Sep; 40(15):6921-6938. PubMed ID: 33682632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.
    Sajid Jamal QM; Alharbi AH; Ahmad V
    J Biomol Struct Dyn; 2022 Oct; 40(17):7960-7974. PubMed ID: 33826483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Kumar R; Kumar R; Tanwar P
    J Biomol Struct Dyn; 2022 Oct; 40(16):7394-7407. PubMed ID: 33715592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.